Doseology announces listing on the Frankfurt Stock Exchange


Doseology Sciences Inc. (CSE: MOOD)

VERNON, BRITISH COLUMBIA, CANADA, March 17, 2022 / — Doseology Sciences Inc. (CSE: MOOD) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on health and wellness, is pleased to announce that its ordinary shares began trading on the Frankfurt Stock Exchange (“FSE”) under the symbol VU7 (V/U/Seven) today.

“We are delighted to be listed on the Frankfurt Stock Exchange and to trade in Europe, where many of our larger competitors have significantly higher trading multiples. ESF listing is an important step for the company, as it allows us to grow our investor base, improve our liquidity and, more broadly, showcase our unique global brand to the European financial community,” said said Ralph Olson, CEO of Dosage. “This additional quote will help increase our visibility and open doors for exciting new business opportunities,” added Olson.

The Frankfurt Stock Exchange is one of the largest securities trading centers in the world and the largest stock exchange in Germany. It facilitates advanced electronic trading, settlement and information systems, enabling it to meet the growing demands of cross-border trade.

The listing of Doseology shares on the FSE represents the first step in the Company’s capital markets strategy to improve access and awareness of the Company’s shares to global investors.

Investors can visit the FSE website here:

About Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD) is building a progressive brand focused on health and wellness through cultivation, extraction, and innovative nutraceuticals and pharmaceuticals. Doseology aims to have a significant impact on the mental health pandemic by using and developing psychedelic and non-psychedelic compounds in the functional mushroom and plant-derived drug markets. With a vertically integrated approach, Doseology intends to process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high quality production. Doseology’s medicinal mushroom products, including tinctures, powders and supplements, are available at

For more information, contact:

Investor Relations: [email protected]
General inquiries: [email protected]
Phone: 236-349-0064

Forward-looking statements

This press release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, ” wait” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts, but rather reflects the Company’s management’s expectations, estimates or projections regarding the business of future results or events of the Company based on opinions, management’s assumptions and estimates considered reasonable at the date the statements are made. In particular, and without limitation, this press release contains forward-looking statements relating to the listing of the Company’s shares on the FSE. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in financial markets; declines in prevailing prices for products in the markets in which the Company operates; adverse changes in applicable laws or adverse changes in the application or enforcement of applicable laws; regulations and enforcement priorities of governmental authorities; compliance with government regulations and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may differ materially from those described herein as anticipated, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be those anticipated, estimated or planned. The Company does not intend and undertakes no obligation to update this forward-looking information, except as otherwise required by applicable law.

No securities regulatory authority has approved or disapproved of the contents of this press release. The securities of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities law, and may not be offered or sold in the United States. United States, or to or on behalf of or for the benefit of any person in the United States, absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

CSE does not accept responsibility for the adequacy or accuracy of this release.

Ralph Olson
Dosology Sciences Inc
+1 236-349-0064
write to us here
Visit us on social media:


Comments are closed.